These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

402 related articles for article (PubMed ID: 1282635)

  • 1. Role of bradykinin in the cardiac effects of angiotensin-converting enzyme inhibitors.
    Linz W; Schölkens BA
    J Cardiovasc Pharmacol; 1992; 20 Suppl 9():S83-90. PubMed ID: 1282635
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Contribution of kinins to the cardiovascular actions of angiotensin-converting enzyme inhibitors.
    Linz W; Wiemer G; Gohlke P; Unger T; Schölkens BA
    Pharmacol Rev; 1995 Mar; 47(1):25-49. PubMed ID: 7784479
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The role of bradykinin and nitric oxide in the cardioprotective action of ACE inhibitors.
    Hartman JC
    Ann Thorac Surg; 1995 Sep; 60(3):789-92. PubMed ID: 7545893
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Contribution of bradykinin to the cardiovascular effects of ramipril.
    Linz W; Wiemer G; Schölkens BA
    J Cardiovasc Pharmacol; 1993; 22 Suppl 9():S1-8. PubMed ID: 7514234
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Local inhibition of bradykinin degradation in ischemic hearts.
    Linz W; Martorana PA; Schölkens BA
    J Cardiovasc Pharmacol; 1990; 15 Suppl 6():S99-109. PubMed ID: 1697370
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Role of endothelium-derived bradykinin in the control of vascular tone.
    Hecker M; Dambacher T; Busse R
    J Cardiovasc Pharmacol; 1992; 20 Suppl 9():S55-61. PubMed ID: 1282631
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Cardioprotective effects of ACE inhibitors: experimental proof and clinical perspectives.
    Schölkens BA; Linz W
    Clin Physiol Biochem; 1990; 8 Suppl 1():33-43. PubMed ID: 2147878
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Suppression of choroidal neovascularization by inhibiting angiotensin-converting enzyme: minimal role of bradykinin.
    Nagai N; Oike Y; Izumi-Nagai K; Koto T; Satofuka S; Shinoda H; Noda K; Ozawa Y; Inoue M; Tsubota K; Ishida S
    Invest Ophthalmol Vis Sci; 2007 May; 48(5):2321-6. PubMed ID: 17460297
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Kinin-related effects of angiotensin-converting enzyme inhibition.
    Bönner G
    Clin Physiol Biochem; 1990; 8 Suppl 1():6-15. PubMed ID: 2257722
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Endothelium-derived bradykinin: implications for angiotensin-converting enzyme-inhibitor therapy.
    Busse R; Fleming I; Hecker M
    J Cardiovasc Pharmacol; 1993; 22 Suppl 5():S31-6. PubMed ID: 7508049
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Inhibition of angiotensin-converting enzyme reduces rat liver reperfusion injury via bradykinin-2-receptor.
    Freise H; Palmes D; Spiegel HU
    J Surg Res; 2006 Aug; 134(2):231-7. PubMed ID: 16513137
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Converting enzyme inhibitor-stimulated formation of nitric oxide and prostacyclin in endothelial cells from bovine aorta is mediated by endothelium-derived bradykinin.
    Wiemer G; Schölkens BA; Becker RH
    Agents Actions Suppl; 1992; 38 ( Pt 3)():196-200. PubMed ID: 1334350
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [ACE inhibition: mechanisms of "cardioprotection" in acute myocardial ischemia].
    Schölkens BA; Linz W
    Klin Wochenschr; 1991; 69 Suppl 24():1-5. PubMed ID: 1865630
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Cardioprotective effects by ramipril after ischemia and reperfusion in animal experiment studies].
    Linz W; Wiemer G; Gohlke P; Unger T; Schölkens BA
    Z Kardiol; 1994; 83 Suppl 4():53-6. PubMed ID: 7856280
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Kinin-mediated coronary nitric oxide production contributes to the therapeutic action of angiotensin-converting enzyme and neutral endopeptidase inhibitors and amlodipine in the treatment in heart failure.
    Zhang X; Recchia FA; Bernstein R; Xu X; Nasjletti A; Hintze TH
    J Pharmacol Exp Ther; 1999 Feb; 288(2):742-51. PubMed ID: 9918584
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Mechanisms involved in the angiotensin II-independent hypotensive action of ACE inhibitors.
    Hecker M; Pörsti I; Busse R
    Braz J Med Biol Res; 1994 Aug; 27(8):1917-21. PubMed ID: 7749381
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Angiotensin-converting enzyme inhibitors unmask endogenous kinin production by bovine coronary artery endothelium.
    Hecker M; Bara AT; Busse R
    Eur Heart J; 1993 Nov; 14 Suppl I():161-3. PubMed ID: 8293768
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Ramiprilat enhances endothelial autacoid formation by inhibiting breakdown of endothelium-derived bradykinin.
    Wiemer G; Schölkens BA; Becker RH; Busse R
    Hypertension; 1991 Oct; 18(4):558-63. PubMed ID: 1655653
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Reduction of infarct size and remodeling after ramipril].
    Martorana PA; Linz W; Schölkens BA
    Z Kardiol; 1994; 83 Suppl 4():63-4. PubMed ID: 7856282
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Experimental cardiovascular benefits of angiotensin-converting enzyme inhibitors: beyond blood pressure reduction.
    Schölkens BA; Linz W; Martorana PA
    J Cardiovasc Pharmacol; 1991; 18 Suppl 2():S26-30. PubMed ID: 1725038
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 21.